Liminatus Pharma
LIMN | NASDAQ
$3.04
+$0.05 (+1.67%)
At close: Nov 16, 2026, 3:59 PM ET
$2.99
-$0.05 (-1.58%)
After-hours:
Nov 16, 2026, 7:41 PM ET
+1.67%
(1D)No price chart data available for 1D timeframe.
Rating
10.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #1018/1021 (Top 100%)
Key Statistics
Market Data
Market Cap $4.08M
1D Range
2.92 3.13
52W Range
2.52 102.50
Valuation (TTM)
PE -0.13
PB 13.58
EV/EBITDA -0.20
Valuation (NTM)
Forward PE N/A
Forward PEG -0.00
Price Target $0.00
Cash Flow
FCF Yield -97.6%
SBC Adj. FCF Yield -97.6%
SBC Impact N/A
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -42.9% |
N/A
FCF 3Y | 5Y -11.0% |
N/A
Returns
ROA -367.9%
ROE 443.6%
ROIC -225.1%
Financial Health
Net Cash
$1.57M
Current Ratio 1.12
Interest Coverage -53.78
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, C...
Sector Healthcare
Industry Biotechnology
Employees 1
IPO Date May 1, 2025
Website liminatuspharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove LIMN